StocksIDEXX Laboratories IncIDXX

IDXX

IDEXX Laboratories Inc

586.54 -12.47 (-2.08%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
585.50
B
587.49

Overview

Prev Close586.54
Day's Range575.03 - 604.95
52 Week Range437.09 - 705.52
Average Volume (3m)391.23K
1-Year Return27.64%
Beta0.9007
Market Cap49.73B
P/E Ratio67.23
Revenue3.14B
EPS8.7247
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Medical Specialties
CEO Jonathan J. Mazelsky, MBA
Employees 9,300

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2020: IDEXX Laboratories Inc's revenues increased by 12.45% and amounted to 2.71B. Net income increased by 36.08% to 582.13M. Net assets decreased by NaN to 632.80M and EPS increased from 4.89 to 6.71.
IDXX's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
59.04%
Net Profit Margin
16.43%
Operating Margin
29.55%
Return On Investment
47.92%
12/20
03/21
06/21
09/21
Total Revenue
720.94M
777.71M
826.14M
810.42M
Gross Profit
411.24M
470.78M
489.31M
472.92M
Operating Income
186.83M
N/A
259.25M
N/A
Net Income
174.96M
204.29M
202.61M
175.18M